Iron depletion and interferon (IFN) therapy: A multicenter, randomized trial in “naive” patients with chronic hepatitis C
Silvia Fargion(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), C Trischitta, Anna Ludovica Fracanzani(University of Milan), M. Ballarè(Ospedale di Mirano), Roberto Ceriani(Paoli Hospital), Mauro Borzio(Ospedale Papa Giovanni XXIII), Michela Mattioli(Italian Institute of Technology), Oliviero Riggio(Sapienza University of Rome), Angelo Rossini(Centro Universitário Barão de Mauá), G Belloni, Franco Bissoli(Azienda Ospedaliera Ospedale Civile di Legnano), G. Fiorelli(IRCCS Policlinico San Donato), Marco Massari(Azienda Sanitaria Unità Locale di Reggio Emilia)
Cited by 1
Related Papers
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
ESPEN Guidelines on Enteral Nutrition: Liver disease
|Clinical Nutrition|2006|683
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661